The efficacy of dulaglutide in diabetic patients

The efficacy of dulaglutide in diabetic patients - The efficacy of dulaglutide in diabetic patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019975

Enrollment

Registered

2015-12-01

Start date

2015-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetic patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Fresh cases for GLP-1 receptor agonist: Patients with poor glycemic control after two months on dietary and exercise therapy 2) Supplementation case for GLP-1 receptor agonist: Patients with poor glycemic control on treatment with antidiabetic agents except GLP-1 receptor agonist 3) Cases whose treatment is changed from other GLP-1 receptor agonist 4) The criteria of poor glycemic control: HbA1c level exceeding 7.0% and/or glycated albumin level exceeding 21.0%

Exclusion criteria

Exclusion criteria: Patients having infectious diseases, thyroid disease, or malignant tumors. Patients being treated with steroids.

Design outcomes

Primary

Measure	Time frame
The primary end-point is plasma glucose, glycated albumin or HbA1c measurement twelve weeks after new, additional administration of dulaglutide and change from other GLP-1 receptor agonist in type 2 diabetic patients.	—

Secondary

Measure	Time frame
Other laboratory data and adverse events will be analyzed as well.	—

Countries

Japan

Contacts

Public ContactAkiko Miyajima

Kawashima Hospital The general affairs division

a.miyajima@khg.or.jp088-631-0110

Outcome results